Loading...
•
Mar 31, 2024
Amneal Q1 2024 Earnings Report
Amneal reported record levels of revenues and double-digit top-line growth across all three segments.
Key Takeaways
Amneal Pharmaceuticals, Inc. announced strong first quarter 2024 results, with net revenue of $659 million, an 18% increase compared to the first quarter of 2023. All three segments experienced double-digit top-line growth. The company reached a settlement in principle on a nationwide opioids settlement and affirmed its 2024 full year guidance.
Net revenue for Q1 2024 reached $659 million, an 18% increase year-over-year.
GAAP net loss was $92 million, including a $94 million pre-tax charge for an opioids settlement.
Adjusted EBITDA increased by 31% to $152 million.
Adjusted diluted EPS was $0.14, compared to $0.12 in the first quarter of 2023.
Amneal
Amneal
Amneal Revenue by Segment
Revenue by Segment
Affordable Medicines Revenue
CapyFin.comSpecialty Revenue
CapyFin.comAvKARE Revenue
CapyFin.com Forward Guidance
The Company is affirming its previously provided full year 2024 guidance.
Positive Outlook
- Net revenue: $2.55 billion - $2.65 billion
- Adjusted EBITDA: $580 million - $620 million
- Adjusted diluted EPS: $0.53 - $0.63
- Operating cash flow: $260 million - $300 million
- Capital expenditures: $60 million - $70 million
Revenue & Expenses
Visualization of income flow from segment revenue to net income